Download PDF
NOTARZT 2000; 16(6): 173-176
DOI: 10.1055/s-2000-8309
ORIGINALIA
Originalia
Georg Thieme Verlag Stuttgart · New York

3,4-Methylendioxymethamphetamin (Ecstasy): Wirkung, Gefahren und präklinische Therapie der akuten Intoxikation

S. Halbig, C. Byhahn, V. Lischke, K. Westphal, P. Kessler
  • Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Klinikum der J. W.-Goethe-Universität, Frankfurt
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

3,4-Methylendioxymethamphetamin (MDMA, Ecstasy) findet in den letzten 15 Jahren auch in Deutschland als so genannte Partydroge zunehmend Verbreitung. Die Substanz greift in den zentralen Serotoninstoffwechsel ein, steigert als indirektes Sympathomimetikum die Freisetzung von Noradrenalin und hemmt dessen Wiederaufnahme und oxidativen Abbau. Im niedrig dosierten Bereich dient Ecstasy als Stimmungsaufheller und Wachmacher. Werden diese Dosen überschritten, können schwere und bedrohliche Nebenwirkungen wie Psychosen, intrazerebrale Ischämien oder Blutungen, renale und hepatische Funktionsstörungen, kardiozirkulatorische Dekompensationen sowie ein malignes Hyperthermiesyndrom auftreten. Die präklinische Therapie der akuten Intoxikation erfolgt symptomatisch.

3,4-Methylenedioxymethamphetamine (Ecstasy): Pharmacokinetics, Side Effects, and Prehospital Treatment of Acute Intoxication

Within the last 15 years in Germany, 3,4-Methylenedioxymethamphetamine (MI)MA, Ecstasy) is increasingly being consumed for recreational use. Acting as an indirect adrenergic agonist, MDMA increases norepinephrine release and decreases norepinephrine reuptake and oxidative decarboxylation. Furthermore, MDMA affects serotonin metabolism. If a small dose is consumed, MDMA stimulates the central nervous system, but overdose may cause lifethreatening poisoning. Symptoms of intoxication consist of neurologic disorders, seizures, cerebral ischemia and hemorrhage, renal and hepatic dysfunction, cardiocirculatory depression, malignant hyperthermia, and even death may occur. Since prehospital diagnosis of MDMA-intoxication is virtually impossible and no antagonistic agents are yet available, treatment is symptomatic.

Schlüsselwörter

Designerdrogen - Ecstasy - Intoxikation - präklinische Therapie

Key words

Designer Drugs - Ecstasy - Intoxication - preclinic therapy

Literatur

  • 1 Ames D, Wirshing W C. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome - a possible link?.  JAMA. 1993;  269 869-870
    CrossrefPubMedGoogle Scholar
  • 2 Bronson M E, Barrios-Zambrano L, Jiang W, Clark C R, DeRuiter J, Newland M C. Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives.  Drug Alcohol Depend. 1994;  36 161-166
    PubMedGoogle Scholar
  • 3  Büro für Suchtprävention. Ecstasy - Prävention des Missbrauchs. Neuland Geesthachst; 1995
    Google Scholar
  • 4 Campkin N J, Davies U M. Treatment of „ecstasy” overdose with dantrolene.  Anaesthesia. 1993;  48 82-83
    PubMedGoogle Scholar
  • 5 Campkin N T, Davies U M. Another death from ecstasy.  J R Soc Med. 1992;  85 61
    PubMedGoogle Scholar
  • 6 Colado M I, Green A R. A study of the mechanism of MDMA („ecstasy”)-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds.  Br J Pharmacol. 1994;  111 131-136
    PubMedGoogle Scholar
  • 7 Dinse H. Ecstasy (MDMA)-Intoxikation.  Anaesthesist. 1997;  46 697-703
    CrossrefPubMedGoogle Scholar
  • 8 Drake W M, Broadhurst P A. QT-interval prolongation with Ecstasy.  S Afr Med J. 1996;  86 180-181
    PubMedGoogle Scholar
  • 9 Dykhuizen R S, Brunt P W, Atkinson P, Simpson J G, Smith C C. Ecstasy induced hepatitis mimicking viral hepatitis.  Gut. 1995;  36 939-941
    PubMedGoogle Scholar
  • 10 Ellis A J, Wendon J A, Portmann B, Williams R. Acute liver damage and ecstasy ingestion.  Gut. 1996;  38 454-458
    PubMedGoogle Scholar
  • 11 Fahal I H, Sallomi D F, Yaqoob M, Bell G M. Acute renal failure after ecstasy.  BMJ . 1992;  305 29
    PubMedGoogle Scholar
  • 12 Gledhill J A, Moore D F, Bell D, Henry J A. Subarachnoid haemorrhage associated with MDMA abuse.  J Neurol Neurosurg Psychiatry. 1993;  56 1036-1037
    PubMedGoogle Scholar
  • 13 Heinz T W. Auswirkungen des Konsums von „Designerdrogen”.  Dt Ärztebl. 1996;  93 358-360
    PubMedGoogle Scholar
  • 14 Henry J A, Jeffreys K J, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine („ecstasy”).  Lancet. 1992;  340 384-387
    CrossrefPubMedGoogle Scholar
  • 15 Henry J A. Ecstasy and the dance of death.  BMJ. 1992;  305 5-6
    PubMedGoogle Scholar
  • 16 Holden R, Jackson M A. Near-fatal hyponatraemic coma due to vasopressin oversecretion after ecstasy” (3,4-MDMA).  Lancet. 1996;  347 1052
    PubMedGoogle Scholar
  • 17 Hughes J C, McCabe M, Evans R J. Intracranial haemorrhage associated with ingestion of „ecstasy”.  Arch Emerg Med. 1993;  10 372-374
    PubMedGoogle Scholar
  • 18 Kessel B. Hyponatraemia after ingestion of ecstasy.  BMJ. 1994;  308 414
    PubMedGoogle Scholar
  • 19 Larner A J. Dantrolene and „ecstasy” overdose.  Anaesthesia. 1993;  48 179-180
    PubMedGoogle Scholar
  • 20 Lee J W. Catatonic stupor after „ecstasy”.  BMJ. 1994;  308 717-718
    PubMedGoogle Scholar
  • 21 Logan A S, Stickle B, O'Keefe N, Hewitson H. Survival following „Ecstasy” ingestion with a peak temperature of 42 degrees C.  Anaesthesia. 1993;  48 1017-1018
    PubMedGoogle Scholar
  • 22 Manchandra S, Connolly M J. Cerebral infarction in association with Ecstasy abuse.  Postgrad Med J. 1993;  69 874-875
    PubMedGoogle Scholar
  • 23 Marsh J C, Abboudi Z H, Gibson F M, Scopes J, Daly S, O'Shaunnessy D F, Baughan A S, Gordon-Smith E C. Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine („Ecstasy”).  Br J Haematol. 1994;  88 281-285
    PubMedGoogle Scholar
  • 24 Maxwell D L, Polkey M I, Henry J A. Hyponatraemia and catatonic stupor after taking „ecstasy”.  BMJ. 1993;  307 1399
    PubMedGoogle Scholar
  • 25 McCann D U, Ricaurte G A. MDMA („ecstasy”) and panic disorder: induction by a single dose.  Biol Psychiatry. 1992;  32 950-953
    CrossrefPubMedGoogle Scholar
  • 26 McCann D U, Ridenour A, Shaham Y, Ricaurte G A. Serotonin neurotoxicity after (±)3'4-methylenedioxymethamphetamine (MDMA; „Ecstasy”): a controlled study in humans.  Neuropsychpharmacology. 1994;  10 129-138
    PubMedGoogle Scholar
  • 27 Nash J F, Yamamoto B K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine.  Brain Res. 1992;  58 1237-243
    PubMedGoogle Scholar
  • 28 Nimmo S M, Kennedy B W, Tullett W M, Blyth A S, Dougall J R. Drug-induced hyperthermia.  Anaesthesia. 1993;  48 892-895
    PubMedGoogle Scholar
  • 29 Rothwell P M, Grant R. Cerebral venous sinus thrombosis induced by „ecstasy”.  J Neurol Neurosurg Psychiatry. 1993;  56 1035
    PubMedGoogle Scholar
  • 30 Rudnick G, Wall S C. The molecular mechanism of „ecstasy” (3,4-methylenedioxymethamphetamine [MDMA]): serotonin transporters are targets for MDMA-induced serotonin release.  Proc Natl Acad Sci USA. 1992;  89 1817-1821
    PubMedGoogle Scholar
  • 31 Sahihi A. Designerdrogen. Heyne München; 1995
    Google Scholar
  • 32 Screaton G R, Singer M, Cairns H S, Thrasher A, Sarner M, Cohen S L. Hyperpyrexia and rhabdomyolysis after 3,4-methylenedioxymethamphetamine („ecstasy”) abuse.  Lancet.. 1991;  339 677-678
    PubMedGoogle Scholar
  • 33 Sternbach G L, Varon J V. Designer drugs. Recognizing and managing their toxic effects.  Postgrad Med. 1992;  91 169-176
    PubMedGoogle Scholar
  • 34 Stone R J. Treatment of „ecstasy” overdose with dantrolene.  Anaesthesia. 1993;  48 83
    PubMedGoogle Scholar
  • 35 Tehan B. Ecstasy and dantrolene.  BMJ. 1993;  306 146
    PubMedGoogle Scholar
  • 36 Watson J D, Ferguson C, Hinds C J, Skinner R, Coakley J H. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place?.  Anaesthesia. 1993;  48 1057-1060
    PubMedGoogle Scholar
  • 37 Webb C, Williams V. Ecstasy intoxication: appreciation of complications and the role of dantrolene.  Anaesthesia. 1993;  48 542-543
    PubMedGoogle Scholar
  • 38 Whitaker-Azmitia P M, Aronson T A. „Ecstasy” (MDMA)-induced panic.  Am J Psychiatry. 1989;  146 119
    PubMedGoogle Scholar
  • 39 Williams H, Meagher D, Galligan P. M.D.M.A. („Ecstasy”): a case of possible druginduced psychosis.  Ir J Med Sci. 1993;  162 43-44
    PubMedGoogle Scholar
  • 40 Winstock A R. Chronic paranoid psychosis after misuse of MDMA.  BMJ. 1991;  302 1150-1151
    PubMedGoogle Scholar
  • 41 Woodrow G, Harnden P, Turney J H. Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine („ecstasy”).  Nephrol Dial Transplant. 1995;  10 399-400
    PubMedGoogle Scholar

Dr. med. Christian Byhahn

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie

Klinikum der J. W. Goethe-Universität

Theodor-Stern-Kai 7

60590 Frankfurt

Email: c.byhahn@em.uni-frankfurt.de

      >